Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, non-randomized, open-label, single-arm study in patients with metastatic
renal cell carcinoma who have received one prior targeted therapy with either sunitinib or
bevacizumab. The planned enrollment for this study is 60 patients.